Obalon Therapeutics Inc.
Obalon Therapeutics Inc. is listed today as Vyome Holdings, Inc: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2018 | $10 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Aug 2014 | $16 M | No. 4 | $10 to $50 million | equity | SEC | |
| Dec 2012 | $5 M | No. 3 | $2 to $10 million | equity | SEC | |
| May 2012 | $17 M | No. 2 | $10 to $50 million | equity | SEC | |
| Feb 2012 | $2 M | No. 1 | Under $2 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Vyome Holdings, Inc, its revenue in fiscal 2025 came from these product and service lines: Licensing and milestone fees – Luliconazole $120,000 (37%), Royalty income related to above product sales $30,000 (9%).
Annual report (SEC XBRL) · Dec 2025
Obalon Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2018).
SEC Form D · Aug 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2018
Products and services#
No products or services of Obalon Therapeutics Inc. are on record.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Domain Parters VII L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| DP VII Associates LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| InterWest Management Partners X, LLC | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Interwest Partners X LP | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 5 investors.
Largest shareholders today
Institutions holding Vyome Holdings, Inc shares, as of Sep 30, 2026.
- Susquehanna International Group, LLP$0 M0.38%
- Geode Capital Management, LLC$0 M0.36%
- Vanguard Capital Management LLC$0 M0.21%
- Focus Partners Wealth$0 M0.21%
- HRT Financial LP$0 M0.20%
- Vanguard Fiduciary Trust Co$0 M0.17%
- Royal Bank Of Canada$0 M0.08%
- UBS Group AG$0 M0.04%
- Tower Research Capital LLC (TRC)$0 M0.04%
- FMR LLC$0 M0.01%
- Caitong International Asset Management Co., Ltd$0 M0.00%
- Barclays PLC$0 M0.00%
- Robinhood Markets, Inc.$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew Rasdal | President and Chief Executive Officer | Aug 2018 |
| Kelly J. Huang, Ph.D. | Chief Operating Officer | Aug 2018 |
| Mark J. Brister | Chief Technology Officer | Aug 2018 |
| William J. Plovanic | Chief Financial Officer | Aug 2018 |
| Kim Puloma Kamdar | Executive officer | May 2012 |
| Andrew Rasdal | President and Chief Executive Officer | Aug 2018 |
| David J. Moatazedi | Director | Aug 2018 |
| Douglas J. Fisher | Director | Aug 2018 |
| Kim J. Kamdar, Ph.D. | Director | Aug 2018 |
| Les J. Howe | Director | Aug 2018 |
| Raymond J. Dittamore | Director | Aug 2018 |
| Sharon J. Stevenson, DVM Ph.D. | Director | Aug 2018 |
| Doug Puloma Fisher | Director | Oct 2014 |
| Kim Puloma Kamdar | Director | Oct 2014 |
| Sharon Puloma Stevenson | Director | Oct 2014 |
| Douglas C. Puloma Sampson | Director | Mar 2012 |
Went public since 2016. Its SEC number is that of a company listed on a stock exchange.